His main research concerns Internal medicine, Vasculitis, Surgery, Gastroenterology and Systemic vasculitis. His study in Cyclophosphamide, Rheumatology, Rheumatism, Rituximab and Lupus nephritis is carried out as part of his studies in Internal medicine. His work deals with themes such as Antibody, Immunology and Intensive care medicine, which intersect with Vasculitis.
His Gastroenterology research includes elements of Creatinine, Placebo and Azathioprine. His work in Systemic vasculitis covers topics such as Retrospective cohort study which are related to areas like Polyarteritis nodosa. His research investigates the connection between Anti-neutrophil cytoplasmic antibody and topics such as Microscopic polyangiitis that intersect with problems in Granulomatosis with polyangiitis.
His primary areas of study are Internal medicine, Vasculitis, Immunology, Rituximab and Gastroenterology. His research investigates the connection between Internal medicine and topics such as Surgery that intersect with issues in Adverse effect. Vasculitis is a primary field of his research addressed under Pathology.
The various areas that David Jayne examines in his Immunology study include Lupus nephritis, Disease and Clinical trial. His studies in Rituximab integrate themes in fields like Hypogammaglobulinemia, Autoimmune disease and Prednisone. His work carried out in the field of Gastroenterology brings together such families of science as Creatinine, Kidney and Renal function.
His primary scientific interests are in Internal medicine, Vasculitis, Rituximab, Granulomatosis with polyangiitis and Microscopic polyangiitis. His Internal medicine study frequently draws connections to other fields, such as Gastroenterology. His Vasculitis study combines topics from a wide range of disciplines, such as Cyclophosphamide and Immunology.
His Rituximab research is multidisciplinary, relying on both Prednisolone, Hypogammaglobulinemia, Azathioprine, Prednisone and Dosing. David Jayne works mostly in the field of Granulomatosis with polyangiitis, limiting it down to concerns involving Eosinophilic and, occasionally, Myeloperoxidase and Proteinase 3. His Systemic vasculitis study which covers Regimen that intersects with Prospective cohort study.
David Jayne focuses on Internal medicine, Vasculitis, Rituximab, Microscopic polyangiitis and Granulomatosis with polyangiitis. His study ties his expertise on Gastroenterology together with the subject of Internal medicine. His Vasculitis study frequently draws parallels with other fields, such as Immunology.
The Rituximab study combines topics in areas such as Maintenance therapy, Azathioprine, ANCA-Associated Vasculitis and Cyclophosphamide. His Microscopic polyangiitis research incorporates themes from Alternative complement pathway, Complement factor B, Complement system, Anti-neutrophil cytoplasmic antibody and Systemic vasculitis. His Granulomatosis with polyangiitis research is multidisciplinary, incorporating perspectives in Mononeuritis Multiplex, Polyarthritis, Asthma, Properdin and Complement membrane attack complex.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides
J. C. Jennette;R. J. Falk;P. A. Bacon;N. Basu.
Arthritis & Rheumatism (2013)
Rituximab versus Cyclophosphamide in ANCA-Associated Renal Vasculitis
Rachel B. Jones;Jan Willem Cohen Tervaert;Thomas Hauser;Raashid Luqmani.
The New England Journal of Medicine (2010)
A Randomized Trial of Maintenance Therapy for Vasculitis Associated with Antineutrophil Cytoplasmic Autoantibodies
David Jayne;Niels Rasmussen;Konrad Andrassy;Paul Bacon.
The New England Journal of Medicine (2003)
EULAR Recommendations for the management of primary small and medium vessel vasculitis
C. Mukhtyar;L. Guillevin;M. C. Cid;B. Dasgupta.
Annals of the Rheumatic Diseases (2009)
Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis
David R.W. Jayne;Gill Gaskin;Niels Rasmussen;Daniel Abramowicz.
Journal of The American Society of Nephrology (2007)
Mycophenolate Mofetil versus Cyclophosphamide for Induction Treatment of Lupus Nephritis
Gerald B. Appel;Gabriel Contreras;Mary Anne Dooley;Ellen M. Ginzler.
Journal of The American Society of Nephrology (2009)
Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis
George K Bertsias;Maria Tektonidou;Zahir Amoura;Martin Aringer.
Annals of the Rheumatic Diseases (2012)
Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody–associated vasculitis
Kirsten De Groot;Niels Rasmussen;Paul A Bacon;Jan Willem Cohen Tervaert.
Arthritis & Rheumatism (2005)
Genetically Distinct Subsets within ANCA-Associated Vasculitis
Paul A Lyons;Tim F Rayner;Sapna Trivedi;Julia U Holle.
The New England Journal of Medicine (2012)
Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial.
Kirsten de Groot;Lorraine Harper;David R.W. Jayne;Luis Felipe Flores Suarez.
Annals of Internal Medicine (2009)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: